Norepinephrine–dopamine reuptake inhibitors (NDRIs)
- Dual NET and DAT blockade with no serotonin transporter action: bupropion, methylphenidate, dexmethylphenidate, solriamfetol
- The serotonin-free profile is why bupropion causes no sexual dysfunction and is not a serotonin-toxicity partner
- Methylphenidate and dexmethylphenidate are the schedule II ADHD stimulants; bupropion treats depression and smoking cessation; solriamfetol treats daytime sleepiness
- Bupropion is a strong CYP2D6 inhibitor — the aripiprazole, atomoxetine, codeine and tamoxifen interactions
- Bupropion lowers the seizure threshold, dose-dependently and with eating disorders; the stimulants carry the misuse and cardiovascular warnings
Class at a glance
- Dual NET and DAT blockade with no serotonin transporter action: bupropion, methylphenidate, dexmethylphenidate, solriamfetol
- The serotonin-free profile is why bupropion causes no sexual dysfunction and is not a serotonin-toxicity partner
Clinical role
- Methylphenidate and dexmethylphenidate are the schedule II ADHD stimulants; bupropion treats depression and smoking cessation; solriamfetol treats daytime sleepiness
- Bupropion is a strong CYP2D6 inhibitor — the aripiprazole, atomoxetine, codeine and tamoxifen interactions
Safety / monitoring
- Bupropion lowers the seizure threshold, dose-dependently and with eating disorders; the stimulants carry the misuse and cardiovascular warnings
Self-check
- Which antidepressant has no serotonin transporter action?
Bupropion — an NDRI, which is why it spares sexual function and does not combine dangerously with an MAOI on serotonin grounds.
Drugs in this class (4)
All drug classes · Open Norepinephrine–dopamine reuptake inhibitors (NDRIs) in the interactive console ↗